Nuvalent to Present First Clinical Data for Next-Generation ALK Inhibitor NVL-655 at AACR-NCI-EORTC Symposium
Key Insights
Nuvalent will present preliminary dose-escalation data from the ALKOVE-1 Phase 1/2 trial of NVL-655, marking the first clinical disclosure for this next-generation ALK (search) inhibitor.
NVL-655 is designed to overcome key limitations of existing ALK (search) inhibitors, including resistance mutations, poor brain penetrance, and CNS adverse events.
The drug targets advanced ALK (search)-positive non-small cell lung cancer and has been engineered to remain active against multiple resistance mutations including the challenging G1202R (search) solvent front mutation.
Nuvalent announced it will present the first clinical data for its investigational ALK (search) inhibitor NVL-655 at the 35th AACR-NCI-EORTC Symposium in Boston this October, marking a significant milestone for the Cambridge-based biopharmaceutical company's lead oncology program.
The presentation will feature preliminary dose-escalation data from the ongoing ALKOVE-1 Phase 1/2 clinical trial, representing the first disclosure of safety and clinical activity data for NVL-655 in patients with advanced ALK (search)-positive non-small cell lung cancer (NSCLC) and other solid tumors.
Addressing Critical Limitations in ALK Inhibition
NVL-655 represents a next-generation approach to ALK (search) inhibition, specifically designed to overcome three major challenges that limit the clinical utility of existing ALK tyrosine kinase inhibitors: treatment-emergent resistance mutations, inadequate brain penetrance, and off-target central nervous system adverse events.
The drug has been engineered to maintain activity against tumors that have developed resistance to first-, second-, and third-generation ALK (search) inhibitors. Notably, NVL-655 is designed to remain effective against the particularly challenging solvent front G1202R (search) mutation, as well as compound mutations including G1202R/L1196M (GRLM), G1202R/G1269A (GRGA), and G1202R/L1198F (GRLF).
Enhanced CNS Penetration and Selectivity
A key differentiating feature of NVL-655 is its optimization for central nervous system penetrance, addressing the critical need for improved treatment options for patients with brain metastases. Brain metastases represent a significant clinical challenge in ALK (search)-positive NSCLC, occurring in approximately 20-30% of patients at diagnosis and up to 60% during the course of disease.
Preclinical studies have demonstrated that NVL-655 selectively inhibits wild-type ALK (search) and its resistance variants while showing reduced activity against the structurally related tropomyosin receptor kinase (TRK (search)) family. This selectivity profile is designed to potentially avoid TRK-related CNS adverse events commonly observed with dual TRK/ALK inhibitors, while potentially driving more durable responses for patients.
Clinical Trial Design and Presentation Details
The ALKOVE-1 trial (NCT05384626) is a first-in-human Phase 1/2 clinical study evaluating NVL-655 in patients with advanced ALK (search)-positive NSCLC and other solid tumors. The Phase 1 portion of the trial continues to enroll patients as the company advances through dose escalation.
The data presentation is scheduled for Friday, October 13, 2023, from 12:30 PM to 4:00 PM during Poster Session B. The presentation, titled "Safety and preliminary activity of the selective ALK (search) inhibitor NVL-655 in patients with ALK fusion-positive solid tumors," will be delivered by Dr. Jessica J. Lin from Massachusetts General Hospital.
Nuvalent plans to host a conference call and webcast on October 13, 2023, with additional details to be announced on the company's website.
Strategic Implications for ALK-Positive Cancer Treatment
The development of NVL-655 addresses a significant unmet medical need in the treatment of ALK (search)-positive cancers. While existing ALK inhibitors have transformed outcomes for patients with ALK-positive NSCLC, resistance mechanisms continue to limit long-term efficacy. The emergence of resistance mutations, particularly the G1202R (search) mutation, represents a major clinical challenge that current therapies struggle to address effectively.
The selective inhibition profile of NVL-655, combined with its brain-penetrant properties, positions the drug as a potential solution for patients who have exhausted current treatment options or who present with CNS involvement at diagnosis.